Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10549-10556
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10549
Table 2 Treatment effects for patients treated with vancomycin (only) or vancomycin and teicoplanin, n (%)
| Group | Number of cases | Markedly effective | Effective | Ineffective | Total efficiency |
| Study group | 43 | 26 (60.47) | 14 (32.56) | 3 (6.98) | 40 (93.02) |
| Control group | 43 | 18 (41.86) | 15 (34.88) | 10 (23.26) | 33 (76.74) |
| χ2 value | 4.441 | ||||
| P value | 0.035 |
- Citation: Wu W, Liu M, Geng JJ, Wang M. Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections. World J Clin Cases 2021; 9(34): 10549-10556
- URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10549.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10549